Point Biopharma will use Lantheus Medical Imaging's PyL (F-18 DCFPyL) radiopharmaceutical in its phase III clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
The multicenter, open-label, randomized clinical trial will evaluate the efficacy and safety of its novel prostate-specific membrane antigen (PSMA)-targeted radioligand radiopharmaceutical, Lu-177 PNT2002, in patients with mCRPC.
PyL, which is an investigational PSMA-targeted small-molecule PET radiopharmaceutical that aims to visualize prostate cancer, will be used to determine PSMA avidity during patient selection. In addition, it will be used to evaluate progression in a subset of patients.
Lantheus subsidiary Progenics Pharmaceuticals will supply PyL at a predetermined supply price.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
